Valuation: Genmab A/S

Market Cap 159B 23.76B 21.21B 19.57B 17.78B 33.35B 2,251B 33.86B 236B 92.86B 1,179B 89.2B 87.29B 3,736B P/E 2026 *
32.4x
P/E 2027 * 22.6x
Enterprise Value 178B 26.72B 23.85B 22B 19.99B 37.5B 2,531B 38.07B 265B 104B 1,326B 100B 98.13B 4,200B EV / Sales 2026 *
5.99x
EV / Sales 2027 * 4.82x
Free-Float
94.3%
Yield 2026 *
-
Yield 2027 * -
1 day+1.30%
1 week+4.94%
Current month+13.27%
1 month+16.45%
3 months+38.88%
6 months+49.48%
Current year+30.93%
1 week 2,473
Extreme 2473
2,665
1 month 2,235
Extreme 2235
2,665
Current year 1,512
Extreme 1512
2,665
1 year 1,512
Extreme 1512
2,665
3 years 1,157
Extreme 1157
2,665
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+1.30%+4.94%+38.23%+28.03% 23.51B
-4.10%-8.35%+38.48%+66.99% 66.22B
-0.41%+4.99%+7.61%+72.82% 55.2B
+0.74%+7.31%+12.50%+88.71% 52.79B
+0.61%+2.69%+27.75%+51.50% 45.53B
-1.08%+2.19%+21.92%+126.56% 43.94B
-3.39%-0.83%+254.27%+922.56% 41.64B
-1.67%+8.06%+14.17%+56.67% 34B
-8.38%-9.01%+25.65%-1.82% 25.84B
-1.77%-0.59%-15.59%-3.08% 22.93B
Average -1.78%+3.38%+42.50%+140.89% 41.16B
Weighted average by Cap. -1.66%+3.40%+44.04%+150.46%

Financials

2026 *2027 *
Net sales 29.76B 4.46B 3.98B 3.67B 3.34B 6.26B 422B 6.35B 44.24B 17.43B 221B 16.74B 16.38B 701B 35.34B 5.3B 4.73B 4.36B 3.96B 7.43B 502B 7.55B 52.53B 20.69B 263B 19.88B 19.45B 833B
Net income 5.06B 758M 676M 624M 567M 1.06B 71.78B 1.08B 7.52B 2.96B 37.61B 2.84B 2.78B 119B 7.28B 1.09B 974M 898M 816M 1.53B 103B 1.55B 10.82B 4.26B 54.14B 4.09B 4.01B 171B
Net Debt 19.71B 2.95B 2.64B 2.43B 2.21B 4.14B 280B 4.21B 29.29B 11.54B 147B 11.08B 10.85B 464B 11.75B 1.76B 1.57B 1.45B 1.32B 2.47B 167B 2.51B 17.47B 6.88B 87.41B 6.61B 6.47B 277B
Projected Income Statement - Annual - Genmab A/S
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-10-22 DKK 2,654.00 +1.30% 124,345
26-10-21 DKK 2,620.00 +0.69% 120,445
26-10-20 DKK 2,602.00 +2.36% 209,947
26-10-19 DKK 2,542.00 +1.60% 104,214
26-10-16 DKK 2,502.00 -1.07% 94,389
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Genmab A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
2,620.00DKK
Average target price
2,775.93DKK
Spread / Average Target
+5.95%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Genmab A/S
  1. Stock Market
  2. Stocks
  3. GMAB Stock